Krystal Biotech reported third quarter 2026 net product revenue of $127.3 million for VYJUVEK and net income of $63.1 million, compared to $79.4 million in the prior year period. The company also announced that its board of directors authorized a share repurchase program of up to $400 million.
Third quarter 2026 net product revenue for VYJUVEK was $127.3 million, up 30% year-over-year.
Net income for the third quarter of 2026 was $63.1 million, or $2.05 per diluted share.
Cash, cash equivalents, and investments totaled $1.2 billion as of September 30, 2026.
The board authorized a share repurchase program of up to $400 million.
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.
From Krystal Biotech's 10-Q and 10-K filings (SEC XBRL). YoY compares each quarter with the same quarter a year earlier; it is blank when the year-ago figure is missing or negative.
Annual results
Fiscal year
Revenue
Growth
EPS (diluted)
Growth
Net margin
FY2025
$389.13M
+33.9%
$6.84
+128.0%
52.6%
FY2024
$290.51M
+473.0%
$3.00
+669.2%
30.7%
FY2023
$50.70M
—
$0.39
—
21.6%
FY2022
$0
—
$-5.49
—
—
FY2021
$0
—
$-3.13
—
—
Frequently asked questions
When is Krystal Biotech's next earnings date?
Krystal Biotech has not announced a report date within the next three weeks. US companies usually report three to six weeks after each quarter ends; this page updates as soon as the date is on the calendar.
What did Krystal Biotech earn last quarter?
For the quarter ended Sep 2026, Krystal Biotech reported diluted EPS of $2.05 (-22.9% year over year) on revenue of $127.34M (+30.2%).
Where do these numbers come from?
Reported revenue, net income and EPS come from the company's own 10-Q and 10-K filings with the SEC (XBRL data). The report date and consensus estimate come from the Nasdaq earnings calendar.
Not investment advice. Figures can be restated by the company in later filings.